Shares of BSE-listed Lupin Ltd were trading up 7.19 per cent on Tuesday morning after the company announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its Goa manufacturing facility.
The inspection of the facility was done in September 2021.
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI). “We are happy to have received the EIR from US FDA with Voluntary Action Indicated classification for our Goa plant. This is a significant milestone as we build back our reputation in Quality and Compliance. We are committed to manufacture and supply products of the highest quality from all our manufacturing sites,” said Vinita Gupta, CEO, Lupin, commenting on the development,
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.